Hematologist
CION Cancer Clinics
AML risk groups and what they predict | CION Cancer Clinics
AML risk groups sort the leukaemia by its chromosome and gene changes into favourable, intermediate and adverse. Favourable means a lower chance of the leukaemia returning after standard chemotherapy, adverse a higher one. The group mainly guides whether a transplant is planned in first remission. It is not a stage and not a personal forecast. This page explains the groups, what changes them, and what they cannot tell you. At CION Cancer Clinics, every leukaemia, MDS and MPN case is reviewed by our haematologist and discussed at a tumour board before a plan is agreed.
BP
Medically reviewed by Dr. Basudev PokhrelConsultant Haematologist · last reviewed September 2026, next review due September 2027
17+specialists on panel
15,000+patients treated
35+centres across Telangana & AP
4.8★ / 800+Google rating
On this page
- What do favourable, intermediate and adverse risk mean in AML?
- What puts someone in each risk group?
- What does the risk group influence, and what does it not?
- Can the risk picture change during treatment?
- What do families often believe about risk groups?
- Which risk-related words will you see?
- What can your risk group not tell you?
- Common questions about AML risk groups
The short answer
What do favourable, intermediate and adverse risk mean in AML?
They are three genetic risk groups that estimate how likely AML is to stay away after standard chemotherapy. Favourable means a lower chance of it coming back, adverse means a higher chance, and intermediate sits between. The group mainly helps your team decide whether a transplant should be planned in first remission.
Where the groups come from
Most haematologists use the European LeukemiaNet (ELN) system, last updated in 2022. It sorts people by the chromosome and gene changes in their leukaemia cells, such as NPM1, FLT3-ITD, CEBPA, TP53 and changes in chromosomes 5, 7 or 17. Your report may say "ELN 2022 favourable" or similar.
What the group is not
It is not a stage, like stage 1 to 4 in other cancers. AML is not staged that way. It is also not a personal forecast. It describes how groups of people with similar gene results have done with standard treatment. Those studies were done in other people, often in other countries, so the group is a guide for planning rather than a prediction about your family.
When it is decided
The group can only be assigned once the chromosome and gene results are back. Until then, your team plans induction on what is already known. If the family is asked to wait for the group before a transplant talk, that is normal, and it is fair to ask roughly when the results are expected.
The three groups
What puts someone in each risk group?
These are common examples, not the full list. The rules have exceptions, and your haematologist applies them to your whole report.
Favourable
Leukaemia that usually responds well to chemotherapy and is less likely to return.
Typical findings
- NPM1 mutation without FLT3-ITD
- t(8;21) or inv(16), core binding factor AML
- A specific in-frame CEBPA change
Intermediate
Neither clearly favourable nor clearly adverse. Response to the first treatment weighs heavily here.
Typical findings
- FLT3-ITD, with or without NPM1
- t(9;11)
- Changes not listed in other groups
Adverse
Leukaemia that is harder to keep away with chemotherapy alone. Transplant and clinical trials are often discussed early.
Typical findings
- TP53 mutation
- Complex karyotype, many chromosome changes
- Loss of chromosome 5 or 7, or certain myelodysplasia-related genes
Not sure whether this applies to you?
Ask an oncologistSide by side
What does the risk group influence, and what does it not?
It does influence
It does not decide
Whether a transplant is advised in first remission
Whether you are fit enough for a transplant
How long and how intensive the later treatment is
Which induction you start on, before results arrive
How closely leukaemia is tracked after treatment
How your own leukaemia will respond
Whether a clinical trial is worth discussing
How long you or your parent will live
How often counts and marrow are checked later
Whether you will have side effects from treatment
Over time
Can the risk picture change during treatment?
At diagnosis
The genetic group is set from the first marrow sample once chromosome and gene results are complete. This part does not change, even if later tests look different.
After induction
The marrow is checked to see whether remission has been reached. Needing two rounds to get there, or not reaching it, raises concern whatever the starting group.
Measurable residual disease
Sensitive tests look for tiny amounts of leukaemia left. Leftover disease can move a favourable-group patient towards a transplant discussion.
At review
Your team puts the genetic group, response, fitness and donor options together before deciding the next step. Bring the family member who will help you decide, because this meeting often sets the long-term plan.
Leave a number, we will call you
One field. No form to fill in, and no charge for the call.
Commonly believed
What do families often believe about risk groups?
"Favourable means we can relax the treatment."
Favourable risk assumes the full planned treatment is given. Cutting cycles or delaying them on your own can remove the very advantage the group describes.
"Adverse risk means there is no point treating."
Adverse describes a harder road, not a closed door. Many people in this group reach remission, and a transplant or trial may be planned. The group helps your team choose the right path early.
"The internet says the survival for our group is X."
Group figures come from studies in other countries and earlier years, with other treatments. They cannot account for your age, fitness, response or care. Ask your haematologist what they expect for you.
"Intermediate means average, so nothing special is needed."
Intermediate is where response and residual disease testing matter most, and where transplant decisions are often the most finely balanced.
On your report
Which risk-related words will you see?
- ELN 2022
- The European LeukemiaNet risk system your team most likely used.
- Karyotype
- The chromosome picture of the leukaemia cells. "Normal karyotype" means no chromosome change was seen.
- Complex karyotype
- Several unrelated chromosome changes together, usually placing AML in the adverse group.
- CR, or complete remission
- No leukaemia seen in the marrow on standard tests, with counts recovering.
- MRD negative or positive
- Whether sensitive tests still find tiny amounts of leukaemia after treatment.
Being straight with you
What can your risk group not tell you?
Your risk group cannot tell you what will happen to you. It is a starting estimate built from gene results, and it becomes more useful only when it is read with your response to treatment, your fitness and your own wishes.
Why two people in the same group can do differently
Two adults with the same favourable result can have very different courses. One may clear the leukaemia after the first round, while the other needs a second round or develops a serious infection that delays treatment. Heart health, kidney function and how well infections are handled all shape what happens. The group is the same; the person is not.
Who the system fits less well
The ELN groups were built mostly from people fit for intensive chemotherapy. For older or less fit adults having lower-intensity treatment, the same labels may predict less, and newer versions for that group are still being studied.
What to ask at your next appointment
Ask which risk group you are in and why, which results are still pending, whether a transplant is being considered, and whether brothers or sisters should be tissue typed now. Ask what would change the plan.
CION's haematology team reviews all results, presents the case at a tumour board and coordinates transplant assessment with qualified centres where it is advised.Questions we are asked
Common questions about AML risk groups
Does favourable risk mean no transplant is needed?
Usually a transplant is not planned in first remission for favourable-risk AML, because chemotherapy alone often keeps it away and a transplant carries its own serious risks. If residual disease stays positive, or the leukaemia returns, a transplant may then be discussed.
How long does it take to know the risk group?
It depends on how quickly chromosome and gene results come back, which can take a week or more. Treatment usually starts before that. Your team will tell you the group once the results are complete, and it is reasonable to ask when they expect them.
Can I move from adverse to favourable?
The genetic group set at diagnosis does not change. What can change is how the leukaemia responds. A good response, with no residual disease found, is encouraging in any group, and a poor response is a concern in any group.
Why is TP53 so important?
A TP53 change makes leukaemia cells less responsive to chemotherapy, so it places AML in the adverse group whatever else is found. Treatment choices may lean towards clinical trials, lower-intensity combinations or transplant. Your haematologist will explain what it means for your plan.
Is risk group the same as the stage of cancer?
No. AML is not staged like solid cancers, because it is in the blood and marrow from the start. The risk group describes the biology of the leukaemia, not how far it has spread. It is the closest AML equivalent to staging in how it guides decisions.
Does age change the risk group?
Age is not part of the genetic group itself. It does matter to the overall picture, because older adults more often have adverse gene changes and may not be fit for intensive treatment. Your team considers age and fitness alongside the group, not inside it.
Should brothers and sisters get tested now?
If you are in the intermediate or adverse group and fit for a transplant, many teams start tissue typing of brothers and sisters early, so there is no delay later. Ask your haematologist. Testing is a blood or cheek-swab sample and is usually arranged through a transplant centre.
Our report does not mention a risk group. Is that wrong?
Not necessarily. The group is often written in the clinical notes rather than on the lab report. Some results may still be pending. Ask your haematologist directly which group they have assigned and which results it is based on.
Your Haematologist
Meet CION's haematologist. One specialist for your blood report and your plan.
Dr. Basudev Pokhrel reviews blood counts, transfusion needs and blood disorders, and works with the CION tumour board on blood cancers.
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationBook an appointment with our specialist
Share your name and number — we'll call you back within 30 minutes to schedule your consultation.
Sources
- National Cancer Institute — Adult Acute Myeloid Leukemia Treatment (PDQ) - Patient Version
- American Cancer Society — Acute Myeloid Leukemia (AML)
- Leukemia & Lymphoma Society — Acute Myeloid Leukemia (AML)
- Cancer.Net — Leukemia - Acute Myeloid - AML
This page is general information, not a prescription. Do not change or stop any treatment based on what you read here. If anything is worrying you, contact your own treating team — or call our helpline and we will help you reach the right specialist.
Keep reading
Related pages
FLT3, NPM1 and IDH in AML: Why Mutations MatterThe gene results that set your groupWhen AML Needs a TransplantHow the risk group feeds the transplant decisionThe Day 14 Marrow: Checking If Induction WorkedHow response to treatment is checkedAML Survival: What the Numbers Mean for YouWhy group figures do not describe one person
Talk to us
Told your AML risk group and unsure what it means?
Share the reports with us. CION's haematology team will explain the group and the questions to ask next. One helpline serves every CION centre.